Business Context and Reporting Period
Company: Nephros, Inc. (NEPH)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Nephros develops and markets high-performance point-of-use water filtration solutions, primarily focusing on medical-grade applications (infection control and dialysis) and commercial markets (foodservice, hospitality). The company relies on a single exclusive supplier, Medica S.p.A., for key filtration materials under a long-term agreement.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Net Revenues | $18,789 | $14,162 |
| Gross Margin | $11,625 | $8,723 |
| Gross Margin % | 62% | 62% |
| Operating Income | $1,146 | $6 |
| Net Income | $1,194 | $74 |
| Cash and Cash Equivalents | $5,400 | $3,760 |
| Working Capital | $8,456 | $6,736 |
| Accumulated Deficit | ($143,138) | ($144,332) |
| Net Cash from Operating Activities | $1,645 | ($492) |
Material Changes vs. Prior Period
- Revenue Growth: Total net revenues increased 33% to $18.8 million, driven by higher programmatic revenue (reorders and new sites), growth in emergency response business, and significant service revenue expansion.
- Profitability: The company achieved a significant turnaround in profitability, with Net Income rising from $74,000 in 2024 to $1.2 million in 2025. Operating income surged from $6,000 to $1.1 million.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 17% ($1.3 million) due to higher sales commissions and bonus accruals. R&D expenses increased 48% ($0.4 million) due to headcount expansion and bonuses.
- Cash Flow: Operating cash flow turned positive, providing $1.6 million in 2025 compared to a $0.5 million outflow in 2024.
- Margin Pressure: While the annual gross margin remained at 62%, management noted margin erosion in the second half of 2025 due to the impact of U.S. tariffs.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management believes current cash balances are sufficient to fund operations for at least the next 12 months. The company anticipates continued tariff impacts on gross margins unless U.S. policy changes.
- Supply Chain Risk: Nephros relies exclusively on Medica S.p.A. for proprietary filter materials. A new agreement extends the term to 2030 with minimum annual purchase commitments ranging from €4.98 million to €6.3 million. Failure to meet these commitments could result in termination.
- Tariff Uncertainty: Following a February 2026 Supreme Court ruling invalidating certain IEEPA-based tariffs, the U.S. administration announced new temporary global tariffs. The company is assessing the impact but has not recognized potential refunds due to uncertainty.
- Internal Control Weakness: The company identified a material weakness in internal controls over financial reporting related to revenue recognition for contracts with multiple performance obligations (products and services). Remediation efforts are underway, but the weakness was not fully remediated as of December 31, 2025.
- Customer Concentration: Three customers accounted for 44% of total revenue in 2025 (Customer A: 22%, Customer B: 12%, Customer C: 10%).
Investor Verification Checklist
- Supplier Dependency: Verify the stability of the exclusive supply agreement with Medica S.p.A. and the company's ability to meet the escalating minimum purchase obligations through 2030.
- Tariff Impact: Monitor the resolution of U.S. tariff policies and the potential for cost pass-throughs to customers or margin compression.
- Revenue Recognition Controls: Assess the progress of remediation regarding the material weakness in revenue recognition controls to ensure future financial reporting accuracy.
- Customer Concentration: Evaluate the risk associated with the top three customers representing nearly half of total revenue.
- Liquidity Runway: Confirm that the $5.4 million cash balance remains sufficient given the company's historical accumulated deficit of $143.1 million.